You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.

    SBC: ARCHER PHARMACEUTICALS, INC.            Topic: NIA

    Pathological hallmarks of Alzheimerandapos;s disease (AD) include extracellular deposits of Aβ peptides, intraneuronal aggregates of abnormally phosphorylated tau protein and neuroinflammation. Most proposed AD disease modifying therapies have focused on strategies that reduce brain Aβ/amyloid or tau pathological accumulation. However, such approaches have been unsuccessful in late stage AD clin ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  2. An Automated Patient Chart Error Detection System for Radiation Therapy

    SBC: Infondrian LLC            Topic: 101

    Project Summary/Abstract Every year, approximately 1,200 severe mistreatments happen in radiation therapy. Radiation therapy lawsuits rank in the top third of all medical specialties with an average of $313,000 per claim settled or litigated. The current method for detecting treatment errors is by a weekly patient chart check, where each treatment record is manually reviewed on a weekly basis. Thi ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Targeting glioblastoma stem-like cells with custom-designed viral vectors

    SBC: Lacerta Therapeutics, Inc.            Topic: 102

    Glioblastoma (GBM) is the most lethal form of adult brain cancers with a median survival of andlt;15 months despite aggressive standard chemoradiation. GBM are formed by GBM stem-like cells (GSCs) - a major contributor to tumor recurrence and a natural focus for therapeutic development. There are two main reasons responsible for treatment failure: 1) high intra- and inter-tumor cellular and molecu ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome

    SBC: Longeveron LLC            Topic: NIA

    The metabolic syndrome (MetS) is a cluster of factors that increases the risks for cardiovascular disease, type 2 diabetes mellitus, and mortality, and currently affects andgt; 40% of US adults. MetS is associated with endothelial dysfunction, decreased circulating endothelial progenitor cells (EPCs), and a pro-inflammatory state. We have made the exciting discovery that therapy with allogeneic me ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Create Ultralong DNA Constructs in One Assembly Step

    SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC            Topic: 400

    Create Ultralong DNA Constructs in One Assembly Step Firebird Biomolecular Sciences LLCSteven ABenner Foundation for Applied Molecular EvolutionShuichi Hoshika AbstractFrost andampSullivan found aglobal market for DNA oligos at $million$million for genesPrivate investment in DNA synthesis companies like TwistGinkgoand DNA Script give collective valuations of several billion dollarsFederal public i ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Receptors, Ligands, and Catalysts on Demand using Expanded Genetic Alphabets

    SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC            Topic: 100

    ABSTRACTTechnology to deliveron demandmolecules that bind targets or catalyze reactions of choice has been a goal of chemistry foryearsEven todaytheory is inadequate to support de novo design of receptors having useful affinity or catalysts having useful turnoverThusmany have sought to create those catalysts on a DNA or RNAcollectivelyxNAusing the Darwinism to these biomolecules to evolveunder lab ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  7. A brief iPad based screening measure for HIV associated neurocognitive disorders

    SBC: Digital Artefacts LLC            Topic: 105

    Despite significance advances in anti retroviral treatments HIV associated neurocognitive disorder HAND remains prevalent and can affect a broad range of everyday activities An effective brief cognitive screen that could be implemented in busy HIV clinics where clinicians have limited time to provide care for patients with complex medical psychiatric and cognitive conditions has the poten ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Therapeutic Neutralization of the Inflammasome After Spinal Cord Injury

    SBC: INFLAMACORE LIMITED LIABILITY COMPANY            Topic: 105

    DESCRIPTION provided by applicant Spinal cord injury SCI is a complex and devastating clinical condition mediated by proinflammatory cytokines that produce neuronal loss axonal destruction and demyelination during the secondary injury cascade There are currently no proven therapies targeting posttraumatic inflammation that have been shown to have clinical value We have previously shown th ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Internet-Based Distributed Quantitative 4D Analysis of Aortic MR/MDCT Images

    SBC: MEDICAL IMAGING APPLICATIONS, LLC            Topic: NHLBI

    Aortic aneurysms and dissections are a cause of frequently preventable death for over 13,000 people annually in the US alone. Many more patients live under a constant threat of a catastrophic aortic event from atheroscle- rotic or congenital causes. Therefore, early and comprehensive diagnosis of morphological or dynamic changes in the aorta is of great importance. This STTR proposal extends and t ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  10. A New Web 2.0 Platform for Analyzing Genomics Data with Application to the S

    SBC: MYATT AND JOHNSON, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): A major research focus for gaining insight into the molecular basis for cancer, with the goal of identifying new treatments, is the systematic profiling of cancer cells. It has resulted in large volumes of data that include the compound potency and gene expression data. To more effectively find treatments, the data must be integrated and associated in context s ...

    STTR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government